Orphan AML Products Face CHMP Questioning

 
• By Maureen Kenny

Companies developing new AML treatments are among those being called before the European Medicines Agency this week for questioning over marketing applications approaching the end of the review process. 

Questions
The EMA has questions for companies about their marketing applications. • Source: Shutterstocks

More from Europe

More from Geography